News

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...
In December 2024, Blarcamesine (ANAVEX2-73) has been accepted for review by the EMA for the treatment of Alzheimer’s disease.
Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...
Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...
Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an ...
Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...
Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...
Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...
Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...
Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...
Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...
After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...